Search Result

Results for "

epidermal growth factor receptor (EGFR)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (51) IGF-1R (1) VEGFR (3) Akt (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (6) Autophagy (1) Bacterial (1) Biochemical Assay Reagents (1) BMX Kinase (1) Btk (1) Calcium Channel (2) Caspase (1) CDK (1) DNA/RNA Synthesis (1) ERK (2) FAK (3) MEK (1) MMP (1) mTOR (1) PERK (1) Phosphatase (2) PI3K (1) PROTACs (2) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (2) Src (3) STAT (1) TAM Receptor (1) Topoisomerase (3) TRP Channel (1)
By Research Areas:	Cancer (51) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (3) Neurological Disease (2)
Click Chemistry:	Alkynes (6)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: EGFR FGFR GHR VEGFR TGF-beta/Smad PDGFR TGF-β Receptor GHSR IGF-1R Nuclear Hormone Receptor 4A/NR4A

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132259

Depatuxizumab mafodotin ABT-414	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used for cancer research .

HY-144680

BLU-945 ZL-2313	EGFR	Cancer
BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC) .

HY-U00002

ZD-4190	VEGFR EGFR	Cancer
ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer.

HY-P9905

Cetuximab Maximum Cited Publications 39 Publications Verification C225	Radionuclide-Drug Conjugates (RDCs) EGFR	Cancer
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .

HY-12806

AG1557	EGFR	Cancer
AG1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has a pIC₅₀ value of 8.194 .

HY-115716

EGFR-IN-17	EGFR	Cancer
EGFR-IN-17 is a potent and selective inhibitor of the **epidermal growth factor receptor ( IC₅₀** 0.0002 μM) to overcome C797S-mediated resistance.

HY-P1085

Epidermal Growth Factor Receptor Peptide (985-996)	EGFR	Cancer
Epidermal Growth Factor Receptor Peptide (985-996) is an amino acid peptide fragment derived from positions 985-996 in epidermal growth factor receptor (EGFR) .

HY-164718

Sevabertinib	EGFR	Cancer
Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity .

HY-160613

EGFR/HER2-IN-11	EGFR	Cancer
EGFR/HER2-IN-11 (compound 20) is an orally active dual inhibitor for human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), with IC₅₀s of 7.7 and 22 nM, respectively. EGFR/HER2-IN-11 exhibits antitumor efficacy and inhibits proliferation against cancer cells BT-474 with GI₅₀ of 601 nM .

HY-169755

Tyrphostin 63	EGFR	Cancer
Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor with IC₅₀ and K_i values are 375 and 123 μM, respectively .

HY-15772S3

Asandeutertinib asandeutertinibum; Osimertinib-d₃; AZD-9291-d₃	EGFR	Cancer
Asandeutertinib (Osimertinib-d3; AZD-9291-d3) is a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with antineoplastic effect .

HY-144048

EGFR-IN-31	EGFR	Cancer
EGFR-IN-31 is a potent inhibitor of *EGFR. Overexpression and mutation of the epidermal* growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-31 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185298A1, compound 2) .

HY-144049

EGFR-IN-32	EGFR	Cancer
EGFR-IN-32 is a potent inhibitor of *EGFR. Overexpression and mutation of the epidermal* growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-32 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185297A1, compound 2) .

HY-P1799

[pTyr5] EGFR (988-993)	Phosphatase	Others
[pTyr5] EGFR (988-993) is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

HY-164527

Si306	Src FAK EGFR	Cancer
Si306 is a Src inhibitor with antitumor activity. Si306 reduces the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), and inhibits the invasion of human glioblastoma (GBM) .

HY-P1799A

[pTyr5] EGFR (988-993) (TFA)	Phosphatase	Others
[pTyr5] EGFR (988-993) TFA is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) TFA is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

HY-100214

EAI001	EGFR	Cancer
EAI001 is a potent, selective mutant **epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC₅₀** value of 24 nM for EGFR ^L858R/T790M. EAI001 can be used for research of cancer .

HY-162099

VEGFR-IN-4	EGFR	Cancer
VEGFR-IN-4 (Compound 6e) is an epidermal growth factor receptor (EGFR) inhibitor. VEGFR-IN-4 has potent antiproliferative activity with an IC₅₀ value of 24.6nM against HCC827 cells .

HY-138916

PF-06672131	Biochemical Assay Reagents EGFR	Others
PF-06672131 is an alkynylated afatinib derivative and a small molecule probe that is reactive to cysteine. PF-06672131 is an inhibitor of epidermal growth factor receptor (EGFR) kinase that targets the ATP pockets of *EGFR*. PF-06672131 can be used for activity-based protein profiling studies .

HY-145867

EGFR-IN-45	Topoisomerase EGFR CDK Apoptosis	Cancer
EGFR-IN-45 is a potent epidermal growth factor receptor (EGFR) pan inhibitor, with IC₅₀s of 0.4 µM and 1.6 µM for *EGFR* and CDK2, respectively. EGFR-IN-45 also inhibit Topo I and Topo II. EGFR-IN-45 arrests cancer cells in the pre-G1 phase and induces apoptosis .

HY-162482

EGFR kinase inhibitor 5	EGFR Apoptosis	Inflammation/Immunology Cancer
EGFR kinase inhibitor 5 (Compound 4c) is an orally active inhibitor for epidermal growth factor receptor (EGFR) kinase, with IC₅₀ of 18.35 μM. EGFR kinase inhibitor 5 induces apoptosis. EGFR kinase inhibitor 5 exhibits anticancer and anti-inflammatory activity with low toxicity (LD₅₀ range: 500-2000 mg/kg) .

HY-162483

EGFR kinase inhibitor 6	EGFR Apoptosis	Inflammation/Immunology Cancer
EGFR kinase inhibitor 6 (Compound 4b) is an orally active inhibitor for epidermal growth factor receptor (EGFR) kinase, with IC₅₀ of 24.34 μM. EGFR kinase inhibitor 6 induces apoptosis. EGFR kinase inhibitor 6 exhibits anticancer and anti-inflammatory activity with low toxicity (LD₅₀ range: 500-2000 mg/kg) .

HY-161633

PROTAC EGFR degrader 11	PROTACs EGFR FAK	Cancer
PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader for epidermal growth factor receptor (EGFR), with DC₅₀ <100 nM. PROTAC EGFR degrader 11 binds CRBN-DDB1 with a K_i of 36 nM. PROTAC EGFR degrader 11 degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibits the proliferation of BaF3 wild type and EGFR mutants, with IC₅₀ <100 nM.

HY-144050

EGFR-IN-33	EGFR	Cancer
EGFR-IN-33 is a potent inhibitor of *EGFR. EGFR-IN-33 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal* growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 13) .

HY-144052

EGFR-IN-35	EGFR	Cancer
EGFR-IN-35 is a potent inhibitor of *EGFR. EGFR-IN-35 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal* growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-35 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 11) .

HY-144051

EGFR-IN-34	EGFR	Cancer
EGFR-IN-34 is a potent inhibitor of *EGFR. EGFR-IN-34 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal* growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-34 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 12) .

HY-144056

EGFR-IN-39	EGFR	Cancer
EGFR-IN-39 is a potent inhibitor of *EGFR. EGFR-IN-39 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal* growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-39 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 2) .

HY-144054

EGFR-IN-37	EGFR	Cancer
EGFR-IN-37 is a potent inhibitor of *EGFR. EGFR-IN-37 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal* growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-37 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 7) .

HY-144055

EGFR-IN-38	EGFR	Cancer
EGFR-IN-38 is a potent inhibitor of *EGFR. EGFR-IN-38 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal* growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-38 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 4) .

HY-161632

PROTAC EGFR degrader 10	PROTACs EGFR FAK	Cancer
PROTAC EGFR degrader 10 (Compound B56) is a PROTAC degrader for epidermal growth factor receptor (EGFR), with DC₅₀ <100 nM. PROTAC EGFR degrader 10 binds CRBN-DDB1 with a K_i of 37 nM. PROTAC EGFR degrader 10 degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibits the proliferation of BaF3 wild type and EGFR mutants, with IC₅₀ <150 nM .

HY-150781

EGFR-IN-71	EGFR	Cancer
EGFR-IN-71 is a potent narrow spectrum epidermal growth factor receptor (EGFR) inhibitor with IC₅₀ values of 3.7 μM. EGFR-IN-71 can be used for researching chordoma . EGFR-IN-71 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-18963

Lavendustin A RG-14355	EGFR	Cancer
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC₅₀ of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .

HY-129510

4-Methyl erlotinib	EGFR	Cancer
4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers .

HY-152098

HX103	EGFR	Cancer
HX103 is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-based fluorogenic probe. HX103 inhibits EGFR 19 del, EGFR L858R, EGFR wild type and EGFR T790M with IC₅₀s of 1.3, 1.5, 4.0 and 977 nM, respectively. HX103 can be used for quantifying active-EGFR to predict agent sensitivity in NSCLC patients with EGFR-activating mutations .

HY-120857

BPIQ-II hydrochloride PD 158294	EGFR	Others
BPIQ-II is a linear imidazoloquinazoline that potently inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR; IC₅₀=8 pM). It is selective for EGFR over an assortment of other tyrosine and serine/threonine kinases. Cellular studies indicate that BPIQ-II can enter cells and very selectively shut down EGF-stimulated signal transmission by binding competitively at the ATP site of EGFR.

HY-19909

NRC-2694	EGFR	Cancer
NRC-2694 is an epidermal growth factor receptor (EGFR) antagonist with anti-cancer and anti-proliferative properties. NRC-2694 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-149517

EGFR/BRAFV600E-IN-2	EGFR	Cancer
E07 aptamer is an aptamer that targets human epidermal growth factor receptor (hEGFR). E07 aptamer can compete with EGF for binding, binds to a novel epitope on EGFR. E07 aptamer binds to cells expressing EGFR, blocks receptor autophosphorylation, and prevents proliferation of tumor cells in three-dimensional matrices. E07 aptamer can be used for tomor disease research .

HY-100499

Tyrphostin AG 528 1 Publications Verification Tyrphostin B66; AG 528	EGFR	Cancer
Tyrphostin AG 528 is an inhibitor of *EGFR* and ErbB2 with IC₅₀s of 4.9 and 2.1 μM, respectively. Tyrphostin AG 528 (Tyrphostin B66) is a protein tyrosine kinase inhibitor, with IC₅₀s of 4.9 μM for **epidermal growth factor receptors (EGFR) and 2.1 μM for ErbB2** . Tyrphostin AG 528 is also an anticancer agent .

HY-19985A

(3S,4S)-PF-06459988	EGFR	Cancer
(3S, 4S)-PF-06459988 is the S enantiomer of PF-06459988 with less active. PF-06459988 is a potent irreversible inhibitor of T790M mutant epidermal growth factor receptor (EGFR). PF-06459988 has excellent selectivity against *EGFR* wild-type while possessing a minimally reactive electrophile that reduces the propensity of off-target labeling .

HY-139300

Epitinib HMPL-813	EGFR	Cancer
Epitinib is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib can be used for the research of cancer . Epitinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-129510R

4-Methyl erlotinib (Standard)	EGFR	Cancer
4-Methyl erlotinib (Standard) is the analytical standard of 4-Methyl erlotinib. This product is intended for research and analytical applications. 4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers .

HY-171124

Tilatamig samrotecan AZD9592	Topoisomerase DNA/RNA Synthesis	Cancer
Tilatamig samrotecan (AZD9592) is an antibody-drug conjugate (ADC) used to deliver topoisomerase I inhibitors (TOP1i), targeting the epidermal growth factor receptor (EGFR) and c-MET, with anti-tumor activity. Tilatamig samrotecan (AZD9592) can induce DNA double-strand breaks, increase the expression of pRAD50 and γH2AX, and inhibit the growth of non-small cell lung cancer .

HY-139300A

Epitinib succinate HMPL-813 succinate	EGFR	Cancer
Epitinib succinate is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer . Epitinib (succinate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-101522

CHMFL-EGFR-202	EGFR BMX Kinase Btk MEK	Cancer
CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC₅₀s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ～10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR, with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines .

HY-170968

EGFR-IN-150	EGFR Apoptosis	Cancer
EGFR-IN-150 is an *EGFR* inhibitor that effectively suppresses the phosphorylation of mutant epidermal growth factor receptor (EGFR) and its downstream AKT signaling pathway, thereby exerting antitumor effects and inducing HMOX1 expression to trigger ferroptosis. EGFR-IN-150 exhibits an IC₅₀ of 0.386 μM against the non-small cell lung cancer (NSCLC) cell line H1975, and significantly inhibits colony formation and migration of both H1975 and A549 cells while inducing apoptosis. In addition, EGFR-IN-150 markedly suppresses tumor growth in the H1975 cell-derived xenograft (CDX) mouse model. EGFR-IN-150 holds promise for research related to non-small cell lung cancer .

HY-150782

UNC-CA359	EGFR	Cancer
UNC-CA359 is a potent **epidermal growth factor receptor** (EGFR) inhibitor, with an IC₅₀ value of 18 nM. UNC-CA359 exhibits strong anti-tumor activity, can be used to Chordoma research . UNC-CA359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-125102

AZ12253801	IGF-1R	Cancer
AZ12253801 is an ATP-competitive IGF-1R tyrosine kinase inhibitor that shows ～10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R-driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC₅₀ of 17 nmol/L. The IC₅₀ for epidermal growth factor receptor (EGFR)-driven proliferation is 440 nmol/L. Anti-tumor activity.

HY-12965B

(Z)-S49076 hydrochloride	TAM Receptor	Cancer
(Z)-S49076 hydrochloride is an orally active inhibitor of MET and AXL that blocks the downstream signaling of these receptors both in vitro and in vivo, inhibiting the proliferation and migration of tumor cells and suppressing tumor growth in xenograft models. (Z)-S49076 hydrochloride is capable of overcoming the resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) due to MET amplification in Erlotinib (HY-50896)-resistant cell lines both in vitro and in vivo. (Z)-S49076 hydrochloride can be used for research in non-small cell lung cancer (NSCLC) .

HY-170438

EGFR-IN-139	EGFR	Cancer
EGFR-IN-139 (compound PD 18) is an **epidermal growth factor receptor (EGFR) inhibitor, with IC₅₀*s of 12.88 (wild type), 10.84 (L858R/T790M), 42.68 (L858R/T790M/C797S) nM, respectively. EGFR-IN-139 displays strong anticancer activity against A549 and H1975 cancer cell lines, which are highly expressed EGFR. EGFR-IN-139 has a strong selectivity to cancer cells. EGFR*-IN-139 can be used for nonsmall cell lung cancer (NSCLC) research_[1].

HY-101959

Tyrphostin AG213 AG213	EGFR Topoisomerase	Cancer
Tyrphostin AG213 (AG213) is an inhibitor of epidermal growth factor receptor (EGFR) protein tyrosine kinase (IC₅₀=0.85 μM). Tyrphostin AG213 inhibits tyrosine kinase activity IC₅₀=2.4 μM) and topoisomerase II (IC₁₀₀=50 μM). Tyrphostin AG213 can induce nonapoptotic cell programmed death in tumor cells .

Cat. No.	Product Name

HY-L075

Anti-Lung Cancer Compound Library

2,239 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 2,239 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P1845

PACAP-38 (31-38), human, mouse, rat	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat can be used for neurotrophic and neuroprotective research .

HY-P1845A

PACAP-38 (31-38), human, mouse, rat TFA	ERK EGFR Reactive Oxygen Species Calcium Channel	Neurological Disease
PACAP-38 (31-38), human, mouse, rat TFA is a PAC₁ receptor activator and increases the α-secretase activity. PACAP-38 (31-38), human, mouse, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP-38 (31-38), human, mouse, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP-38 (31-38), human, mouse, rat TFA can be used for neurotrophic and neuroprotective research .

HY-P1085

Epidermal Growth Factor Receptor Peptide (985-996)	EGFR	Cancer
Epidermal Growth Factor Receptor Peptide (985-996) is an amino acid peptide fragment derived from positions 985-996 in epidermal growth factor receptor (EGFR) .

HY-P1799

[pTyr5] EGFR (988-993)	Phosphatase	Others
[pTyr5] EGFR (988-993) is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

HY-P1799A

[pTyr5] EGFR (988-993) (TFA)	Phosphatase	Others
[pTyr5] EGFR (988-993) TFA is derived from the autophosphorylation site (Tyr992) of epidermal growth factor receptor (EGFR 988-993). [pTyr5] EGFR (988-993) TFA is often complexed with the catalytically inactive protein-tyrosine phosphate 1B (PTP1B) .

Cat. No.	Product Name	Target	Research Area

HY-P9905

Cetuximab 35+ Cited Publications C225	Radionuclide-Drug Conjugates (RDCs) EGFR	Cancer
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18963

Lavendustin A RG-14355	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Disease Research Fields Cancer	EGFR
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC₅₀ of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .

HY-N0447

8-Gingerol 4 Publications Verification	Zingiber officinale Roscoe Structural Classification Monophenols Classification of Application Fields Source classification Phenols Plants Inflammation/Immunology Disease Research Fields Zingiberaceae Cancer	TRP Channel Bacterial Apoptosis Autophagy STAT PERK EGFR PI3K Akt mTOR Caspase MMP
8-Gingerol can be found in the rhizome of ginger (Z. officinale) and has oral bioactivity. It activates TRPV1, with an EC₅₀ value of 5.0 µM. 8-Gingerol inhibits COX-2 and also suppresses the growth of H. pylori in vitro. Additionally, 8-Gingerol exhibits anticancer, antioxidant, and anti-inflammatory properties by inhibiting the epidermal growth factor receptor (EGFR) and modulating its downstream STAT3/ERK pathway to suppress the proliferation, migration, and invasion of colorectal cancer cells. 8-Gingerol also exerts immunosuppressive effects by inhibiting oxidative stress, inducing cell cycle arrest, promoting apoptosis, and regulating autophagy. Furthermore, 8-Gingerol has cardioprotective effects. 8-Gingerol is promising for research in the fields of cancer, infection, immunosuppression, and cardiovascular diseases.

Species:	Human (11) Rhesus Macaque (3) Mouse (2) Rat (1) Cynomolgus (2) Canine (1)
Tag:	His (14) Strep (1) Myc (1) GST (4) Fc (4)
Source:	HEK293 (13) Sf9 insect cells (7)

Cat. No.	Compare	Product Name	Species	Source

HY-P70189

	EGFR vIII Protein, Human (HEK293, His) rHuepidermal growth factor receptor/EGFR vIII, His; epidermal growth factor receptor; EGFR; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EGFR	Human	HEK293
	The EGFRvIII protein is a transmembrane glycoprotein in the protein kinase superfamily that acts as a receptor for epidermal growth factor. It acts on the cell surface, binds to epidermal growth factor, triggers receptor dimerization and tyrosine autophosphorylation, and promotes cell proliferation. EGFR vIII Protein, Human (HEK293, His) is the recombinant human-derived EGFR vIII protein, expressed by HEK293 , with C-6*His labeled tag. The total length of EGFR vIII Protein, Human (HEK293, His) is 354 a.a., with molecular weight of 61-75 kDa.

HY-P72988

	EGFR Protein, Mouse (HEK293, Fc) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Mouse	HEK293
	The EGFR protein is a receptor tyrosine kinase that binds EGF family ligands and activates multiple signaling cascades. Ligand binding induces receptor homo- or heterodimerization, leading to autophosphorylation and recruitment of adapter proteins (such as GRB2). EGFR Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived EGFR protein, expressed by HEK293 , with C-hFc labeled tag. The total length of EGFR Protein, Mouse (HEK293, Fc) is 623 a.a., with molecular weight of ~142.57 kDa.

HY-P72989

	EGFR Protein, Mouse (HEK293, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Mouse	HEK293
	The EGFR protein is a receptor tyrosine kinase that binds EGF family ligands and activates multiple signaling cascades. Ligand binding induces receptor homo- or heterodimerization, leading to autophosphorylation and recruitment of adapter proteins (such as GRB2). EGFR Protein, Mouse (HEK293, His) is the recombinant mouse-derived EGFR protein, expressed by HEK293 , with C-10*His labeled tag.

HY-P72990

	EGFR Protein, Rat (HEK293, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rat	HEK293
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family.EGFR Protein is involved in the regulation of NF-kappa-B , RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs signaling pathways.EGFR Protein has calmodulin binding activity, epidermal growth factor binding activity and epidermal growth factor activating receptor activity.EGFR Protein, Rat (HEK293, His) is the recombinant rat-derived EGFR protein, expressed by HEK293 , with C-His labeled tag.

HY-P75259

	EGFR Protein, Cynomolgus (sf9, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Cynomolgus	Sf9 insect cells
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. EGFR Protein is involved in the regulation of NF-kappa-B , RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs signaling pathways. EGFR Protein has calmodulin binding activity, epidermal growth factor binding activity and epidermal growth factor activating receptor activity. EGFR Protein, Cynomolgus (sf9, His) is the recombinant cynomolgus-derived EGFR protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of EGFR Protein, Cynomolgus (sf9, His) is 621 a.a., with molecular weight of ~70.1 kDa.

HY-P75260

	EGFR Protein, Cynomolgus (HEK293, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Cynomolgus	HEK293
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. EGFR Protein is involved in the regulation of NF-kappa-B , RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs signaling pathways. EGFR Protein has calmodulin binding activity, epidermal growth factor binding activity and epidermal growth factor activating receptor activity. EGFR Protein, Cynomolgus (HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-His labeled tag. The total length of EGFR Protein, Cynomolgus (HEK293, His) is 621 a.a., with molecular weight of ~93.8 kDa.

HY-P72987

	EGFR Protein, Human (sf9, His-GST) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (sf9, His-GST) is the recombinant human-derived EGFR protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of EGFR Protein, Human (sf9, His-GST) is 543 a.a., with molecular weight of ~89.1 kDa.

HY-P72986

	EGFR Protein, Canine (sf9, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Canine	Sf9 insect cells
	EGFR Protein is a receptor tyrosine kinase that binds to ligands of the EGF family. The high expression of EGFR protein can be used as a diagnostic marker for canine transitional cell carcinoma (TCC). EGFR Protein participate in the NF-kappa-B signaling pathway. The high expression of EGFR protein can be used as a diagnostic marker for canine transitional cell carcinoma (TCC). EGFR Protein, Canine (sf9, His) is the recombinant canine-derived EGFR protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of EGFR Protein, Canine (sf9, His) is 618 a.a., with molecular weight of ~87.2 kDa.

HY-P702751

	EGFR Protein, Human (sf9, GST) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (sf9, GST) is the recombinant human-derived EGFR, expressed by Sf9 insect cells , with GST labeled tag. The total length of EGFR Protein, Human (sf9, GST) is 543 a.a.,

HY-P75256

	EGFR Protein, Rhesus Macaque (sf9, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rhesus Macaque	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Rhesus Macaque (sf9, His) is the recombinant Rhesus Macaque-derived EGFR protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P75257

	EGFR Protein, Rhesus Macaque (HEK293, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rhesus Macaque	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived EGFR protein, expressed by HEK293 , with C-10*His labeled tag.

HY-P75258

	EGFR Protein, Rhesus Macaque (HEK293, Fc) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Rhesus Macaque	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived EGFR protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P74177

	EGFR Protein, Human (621a.a, HEK293, Fc) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293, Fc) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-hFc labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, Fc) is 621 a.a., with molecular weight of 110-160 kDa.

HY-P73517

	EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-His labeled tag. The total length of EGFR Protein, Human (Biotinylated, 621a.a, HEK293, His) is 621 a.a., with molecular weight of ~99.5 kDa.

HY-P700409

	EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-Myc, N-10*His labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, N-His, C-Myc) is 621 a.a., with molecular weight of 73.6 kDa.

HY-P700693

	CLEC14A Protein, Human (HEK293, His) epidermal growth factor receptor 5; EGFR-5; EGFR 5; EGFR5; C14orf27; UNQ236; PRO269; CEG1	Human	HEK293

HY-P702832

	EGFR Protein, Human (T790M, L858R, sf9, StreII, GST, His) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (T790M, L858R, sf9, Strep, GST, His) is the recombinant human-derived EGFR, expressed by Sf9 insect cells , with C-8*His, N-GST, N-Strep labeled tag. ,

HY-P70608

	EGFR vIII Protein, Human (HEK293, Fc) 1 Publications Verification epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR vIII protein is a transmembrane glycoprotein in the protein kinase superfamily that acts as a receptor for epidermal growth factor. It acts on the cell surface, binds to epidermal growth factor, triggers receptor dimerization and tyrosine autophosphorylation, and promotes cell proliferation. EGFR vIII Protein, Human (HEK293, Fc) is the recombinant human-derived EGFR vIII protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P702831

	EGFR Protein, Human (C797S, T790M, L858R, sf9, GST) epidermal growth factor receptor; EGFR; ERBB; ERBB1; HER1	Human	Sf9 insect cells
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (C797S, T790M, L858R, sf9, GST) is the recombinant human-derived EGFR, expressed by Sf9 insect cells , with N-GST labeled tag. ,

HY-P70613

	EGFR Protein, Human (621a.a, HEK293, His) epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; ERBB1; HER1	Human	HEK293
	The EGFR protein is a receptor tyrosine kinase that can bind to a variety of ligands, such as EGF, TGFA, AREG, epigen, BTC, epiregulin, and HBEGF, to initiate signaling cascades that mediate cellular responses. This involves receptor dimerization, autophosphorylation and recruitment of adapter proteins such as GRB2, activating downstream pathways such as RAS-RAF-MEK-ERK, PI3-kinase-AKT, PLCgamma-PKC and STAT. EGFR Protein, Human (621a.a, HEK293, His) is the recombinant human-derived EGFR protein, expressed by HEK293 , with C-6*His labeled tag. The total length of EGFR Protein, Human (621a.a, HEK293, His) is 621 a.a., with molecular weight of 90-120 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-15772S3

Asandeutertinib
Asandeutertinib (Osimertinib-d3; AZD-9291-d3) is a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with antineoplastic effect .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80648

	EGFR Antibody (YA775) EGFR; ERBB; ERBB1; HER1; epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1	WB, ICC/IF, IP	Human, Monkey
	EGFR Antibody (YA775) is a non-conjugated and Mouse origined monoclonal antibody about 134 kDa, targeting to EGFR (6H11). It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Monkey.

HY-P80808

	Phospho-EGFR (Tyr1068) Antibody EGFR; ERBB; ERBB1; HER1; epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1	WB, IHC-F, IHC-P, ICC/IF	Human
	Phospho-EGFR (Tyr1068) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Phospho-EGFR (Tyr1068). It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human.

HY-P80809

	Phospho-EGFR (Tyr1092) Antibody EGFR; ERBB; ERBB1; HER1; epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1	WB, IHC-P	Human, Mouse, Rat
	Phospho-EGFR (Tyr1092) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Phospho-EGFR (Tyr1092). It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

HY-P80810

	Phospho-EGFR (Tyr1173) Antibody EGFR; ERBB; ERBB1; HER1; epidermal growth factor receptor; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1	WB, IHC-F, IHC-P, ICC/IF, IP	Human
	Phospho-EGFR (Tyr1173) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to Phospho-EGFR (Tyr1173). It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human.

HY-P80116

	EGFR Antibody 1 Publications Verification Avian erythroblastic leukemia viral (v erb b) oncogene homolog antibody; Cell growth inhibiting protein 40 antibody; Cell proliferation inducing protein 61 antibody; EGF R antibody; EGFR antibody; EGFR_HUMAN antibody; epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog) antibody; epidermal growth factor receptor antibody; erb-b2 receptor tyrosine kinase 1 antibody; ERBB antibody; ERBB1 antibody; Errp antibody; HER1 antibody; mENA antibody; NISBD2 antibody; Oncogen ERBB antibody; PIG61 antibody; Proto-oncogene c-ErbB-1 antibody; receptor tyrosine protein kinase ErbB 1 antibody; receptor tyrosine-protein kinase ErbB-1 antibody; SA7 antibody; Species antigen 7 antibody; Urogastrone antibody; v-erb-b Avian erythroblastic leukemia viral oncogen homolog antibody; wa2 antibody; Wa5 antibody	WB, ICC/IF, IP, FC, mIHC	Human, Mouse, Rat
	EGFR Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 134 kDa, targeting to EGFR. It can be used for WB,ICC/IF,mIHC,IP, FC assays with tag free, in the background of Human, Mouse, Rat.